PET-based classification of corticobasal syndrome.

Alzheimer Disease / metabolism Corticobasal Degeneration Fluorodeoxyglucose F18 Humans Magnetic Resonance Imaging Positron-Emission Tomography tau Proteins / metabolism
(11)C-PBB3 Amyloid Corticobasal degeneration/syndrome (CBD/CBS) Positron emission tomography Tau

Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
05 2022
Historique:
received: 20 10 2021
revised: 16 03 2022
accepted: 21 04 2022
pubmed: 10 5 2022
medline: 15 6 2022
entrez: 9 5 2022
Statut: ppublish

Résumé

Corticobasal degeneration (CBD) is the most common neuropathological substrate for clinically diagnosed corticobasal syndrome (CBS), while identifying CBD pathology in living individuals has been challenging. This study aimed to examine the capability of positron emission tomography (PET) to detect CBD-type tau depositions and neuropathological classification of CBS. Sixteen CBS cases diagnosed by Cambridge's criteria and 12 cognitively healthy controls (HCs) underwent PET scans with Sixteen CBS cases consisted of two cases (13%) with amyloid and tau positivities indicative of Alzheimer's disease (AD) pathologies, 11 cases (69%) with amyloid negativity and tau positivity, and three cases (19%) with amyloid and tau negativities. Amyloid(-), tau(+) CBS cases showed increased retentions of PET-based classification of CBS was in accordance with previous neuropathological reports on the prevalences of AD, non-AD tauopathies, and others in CBS. The current work suggests that

Identifiants

DOI: 10.1016/j.parkreldis.2022.04.015 PMID: 35533530
pubmed: 35533530
pii: S1353-8020(22)00111-0
doi: 10.1016/j.parkreldis.2022.04.015
pii:
doi:

Substances chimiques

tau Proteins 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-98

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Yoshikazu Nakano (Y)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Neurology, Chibaken Saiseikai Narashino Hospital, Narashino, Japan.

Hitoshi Shimada (H)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Functional Neurology & Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.

Hitoshi Shinotoh (H)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Neurology Clinic Chiba, Chiba, Japan.

Shigeki Hirano (S)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.

Kenji Tagai (K)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Yasunori Sano (Y)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Yasuharu Yamamoto (Y)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Hironobu Endo (H)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Kiwamu Matsuoka (K)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Keisuke Takahata (K)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Manabu Kubota (M)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Yuhei Takado (Y)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Yasuyuki Kimura (Y)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; National Center for Geriatrics and Gerontology, Obu, Japan.

Masanori Ichise (M)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Maiko Ono (M)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Naruhiko Sahara (N)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Kazunori Kawamura (K)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Ming-Rong Zhang (MR)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Satoshi Kuwabara (S)

Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.

Tetsuya Suhara (T)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Makoto Higuchi (M)

National Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan. Electronic address: higuchi.makoto@qst.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › PET-based classification of corticobasal syndrome.
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Tauopathies › Dégénérescence corticobasale › PET-based classification of corticobasal syndrome.
questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › PET-based classification of corticobasal syndrome.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PET-based classification of corticobasal syndrome.
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › PET-based classification of corticobasal syndrome.
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › PET-based classification of corticobasal syndrome.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › PET-based classification of corticobasal syndrome.